Upload
finance13
View
827
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Citation preview
1Not for promotional useNot for promotional use
Research & DevelopmentResearch & DevelopmentUpdateUpdate
Elliott Sigal, MD, PhDElliott Sigal, MD, PhDExecutive Vice PresidentExecutive Vice President
Chief Scientific Officer & President, R&DChief Scientific Officer & President, R&D
JP Morgan Healthcare ConferenceJanuary 7, 2008
2Not for promotional useNot for promotional use
During this meeting, we will make statements about the CompanyDuring this meeting, we will make statements about the Company’’s future s future plans and prospects, including statements about our financial poplans and prospects, including statements about our financial position, sition, business strategy, research pipeline concerning product developmbusiness strategy, research pipeline concerning product development and ent and product potential, that constitute forwardproduct potential, that constitute forward--looking statements for purposes looking statements for purposes of the safe harbor provisions under the Private Securities Litigof the safe harbor provisions under the Private Securities Litigation Reform ation Reform Act of 1995.Act of 1995.
Actual results may differ materially from those indicated by theActual results may differ materially from those indicated by these forwardse forward--looking statements as a result of various important factors, inclooking statements as a result of various important factors, including those luding those discussed in the companydiscussed in the company’’s most recent annual report on Form 10s most recent annual report on Form 10--K, K, periodic reports on Form 10periodic reports on Form 10--Q and current reports on Form 8Q and current reports on Form 8--K. These K. These documents are available from the SEC, the Bristoldocuments are available from the SEC, the Bristol--Myers Squibb websiteMyers Squibb websiteor from Bristolor from Bristol--Myers Squibb Investor Relations.Myers Squibb Investor Relations.
In addition, any forwardIn addition, any forward--looking statements represent our estimates only as looking statements represent our estimates only as of today and should not be relied upon as representing our estimof today and should not be relied upon as representing our estimates as of ates as of any subsequent date. While we may elect to update forwardany subsequent date. While we may elect to update forward--looking looking statements at some point in the future, we specifically disclaimstatements at some point in the future, we specifically disclaim any any obligation to do so, even if our estimates change.obligation to do so, even if our estimates change.
3Not for promotional useNot for promotional use
AgendaAgenda
Evolving to the Next Generation Evolving to the Next Generation BioPharmaBioPharma ModelModel
R&D StrategyR&D Strategy
Pipeline UpdatePipeline Update
4Not for promotional useNot for promotional use
Forces Driving Industry ChangeForces Driving Industry Change
Increased regulatory / clinical requirements Increased regulatory / clinical requirements
Decreased access to physicians by sales Decreased access to physicians by sales modelmodel
Increased power of payers on pricing and Increased power of payers on pricing and prescribingprescribing
Consolidation / costConsolidation / cost--reduction across reduction across industryindustry
5Not for promotional useNot for promotional use
Evolution of Biotech and Pharmaceutical Evolution of Biotech and Pharmaceutical CompaniesCompanies
Traditional Biotech
Traditional Large Pharma
MajorBiotechs
’’80s/80s/’’90s90s 2000 2000 –– now now
SmallBiotechs
Mid-CapPharma
MegaPharma
Next Generation
Model
Future ModelFuture Model
More More consolidation?consolidation?
More More consolidation?consolidation?
Focus on Focus on productivity/productivity/
executionexecution
6Not for promotional useNot for promotional use
Next Generation Next Generation BioPharmaBioPharma ModelModel
Next GenerationBioPharma
Best of PharmaBest of Biotech
Innovative Innovative PortfolioPortfolio
Selectively Selectively Integrated Integrated
Business ModelBusiness ModelContinuous Continuous
ImprovementImprovement
Nimble and Entrepreneurial Culture
7Not for promotional useNot for promotional use
Innovative PortfolioInnovative Portfolio
Selectively Selectively IntegratedIntegrated
Business ModelBusiness ModelContinuousContinuous
ImprovementImprovementInnovativeInnovativePortfolioPortfolio
Innovative Portfolio: Implications to R&DFocus is on serious unmet medical needs in specialty and high prevalence disease areasFlexibility to choose the right modality for the right target Generation of clinical and economic data that demonstrate value for payers and patients
Next GenerationBioPharma
8Not for promotional useNot for promotional use
2
1
3
1
2
2
4
6
4
6
1
2
2
4
4
5
3
1
4
1
5
2
0 1 2 3 4 5 6 7 8 9 10 11
J&J
Wyeth
AZ
Roche*
Lilly
S-A
Novartis
GSK
BMS
Merck
Pfizer
PriorityNon-Priority
Record of Priority Review is External Record of Priority Review is External Validation of Innovative PortfolioValidation of Innovative Portfolio Average FDAAverage FDA
Review TimeReview Time(Months)(Months)
1919
88
77
1414
1818
2323
1818
1010
1515
1616
1111
US NME Approvals January 2002 US NME Approvals January 2002 –– October 2007 October 2007 with FDA Review Status and Average Review Timewith FDA Review Status and Average Review Time
Note: Includes compounds designated as classification “1” (NDA chemical type – new molecular entity) by the FDA. Novel biologics and novel vaccines are included.* Includes compounds Genentech filed in the US (i.e., Avastin, Tarceva) for which Roche had significant development participation.Approval for Boniva credited to both Roche and GSK based on co-development agreement.Source: PhRMA, FDA, Company Reports, BMS internal analysis
$7.2$7.2
$4.5$4.5
$6.2$6.2
$4.3$4.3
$5.6$5.6
$3.0$3.0
$5.0$5.0
$2.9$2.9
$3.8$3.8
$4.7$4.7
20062006PharmaPharma
R&D Spend R&D Spend ($B) ($B)
$2.8$2.8
9Not for promotional useNot for promotional use
Selectively Selectively IntegratedIntegrated
Business ModelBusiness ModelContinuousContinuous
ImprovementImprovementInnovativeInnovativePortfolioPortfolio
Selectively Integrated Business ModelSelectively Integrated Business Model
Selectively Integrated Business Model:Implications to R&D
External sources of innovation to complement internal capabilitiesCo-development and co-commercialization partnershipsFocusing internal activities in core, high-value areas
Next GenerationBioPharma
10Not for promotional useNot for promotional use
CoCo--development and Codevelopment and Co--commercialization to commercialization to Optimize the Value of a PipelineOptimize the Value of a Pipeline
Share risk and cost associated with large lateShare risk and cost associated with large late--stage development investmentsstage development investments
Allow greater investment in broader portfolioAllow greater investment in broader portfolio
Make big products even bigger by leveraging Make big products even bigger by leveraging partnerpartner’’s capabilities s capabilities
SaxagliptinSaxagliptinApixabanApixaban DapagliflozinDapagliflozin
11Not for promotional useNot for promotional use
Selectively Selectively IntegratedIntegrated
Business ModelBusiness ModelContinuousContinuous
ImprovementImprovementInnovativeInnovativePortfolioPortfolio
Focus on Continuous ImprovementFocus on Continuous Improvement
Focus on Continuous Improvement: Implications to R&D
Improving yield Increasing cost-effectiveness
Next GenerationBioPharma
12Not for promotional useNot for promotional use
Nine New Drug Approvals inNine New Drug Approvals inLess Than Five YearsLess Than Five Years
20032003 20042004 20052005 20062006 20072007
Otsuka AmericaPharmaceutical, Inc.
ImClone SystemsIncorporated
HIV / AIDS
Schizophrenia, Depression
Cancer
Hepatitis B
Rheumatoid ArthritisHIV / AIDS
Cancer
Cancer
Depression
SomersetPHARMACEUTICALS INC.
13Not for promotional useNot for promotional use
BristolBristol--Myers Squibb R&D Productivity Myers Squibb R&D Productivity Counter to Industry TrendCounter to Industry Trend
Industry based on top 11 pharma companies Industry based on top 11 pharma companies Source: Company reports, PhRMA, BMS internal analysisSource: Company reports, PhRMA, BMS internal analysis
Rolling 3 year totals for Pharma R&D spend vs. U.S. NME approvalRolling 3 year totals for Pharma R&D spend vs. U.S. NME approvalss
$ B
illio
ns$
Bill
ions
$0$0
$1$1
$2$2
$3$3
$4$4
$5$5
$6$6
$7$7
$8$8
$9$9
$10$10
19961996--19981998 19971997--19991999 19981998--20002000 19991999--20012001 20002000--2002200200
11
22
33
44
5566
77
88
99
1010
1111
1212Industry AvgIndustry AvgBMSBMS
3 Yr Pharma R&D Spend3 Yr Pharma R&D Spend 3 Yr R&D NME Approvals3 Yr R&D NME ApprovalsIndustry AvgIndustry AvgBMSBMS
19991999--20012001 20002000--20022002 20012001--20032003 20022002--20042004 20032003--20052005R&D Spend:R&D Spend:
NME Approvals:NME Approvals:20012001--2003200320042004--20062006
NM
E A
ppro
vals
NM
E A
ppro
vals
14Not for promotional useNot for promotional use
Continuous Productivity Occurring Continuous Productivity Occurring CompanyCompany--widewide
Productivity Transformation Team
Management Council
Supply ChainSupply Chain R&DR&D Commercial Commercial OperationsOperations
G&AG&A
$1.5 BillionCost Savings + Cost Avoidance
$400 MM$400 MM $200 MM$200 MM $550 MM$550 MM $350 MM$350 MM
15Not for promotional useNot for promotional use
AgendaAgenda
Evolving to the Next Generation Evolving to the Next Generation BioPharma ModelBioPharma Model
R&D StrategyR&D Strategy
Pipeline UpdatePipeline Update
16Not for promotional useNot for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development ProgramsFull Development Programs
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in overweight and obese
diabetes patients
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than current standard of care
17Not for promotional useNot for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development ProgramsFull Development Programs
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in overweight and obese
diabetes patients
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than current standard of care
18Not for promotional useNot for promotional use
Current Therapies for Solid Organ TransplantCurrent Therapies for Solid Organ Transplant
Significant gains in oneSignificant gains in one--year graft survival rates with year graft survival rates with current therapy current therapy
Less progress on fiveLess progress on five--year patient and graft survivalyear patient and graft survival–– 34% graft loss for deceased donors34% graft loss for deceased donors–– 21% graft loss for living related donors21% graft loss for living related donors
Calcineurin inhibitors (CNIs) are associated withCalcineurin inhibitors (CNIs) are associated withlonglong--term complications term complications
–– Increased risk of chronic allograft nephropathy Increased risk of chronic allograft nephropathy leading to graft loss leading to graft loss
–– Increased risk factors for cardiovascular diseaseIncreased risk factors for cardiovascular disease–– Increased risk of diabetesIncreased risk of diabetes
19Not for promotional useNot for promotional use
Belatacept Showed Comparable Efficacy and Belatacept Showed Comparable Efficacy and Improved Safety Over Cyclosporine at 1 YearImproved Safety Over Cyclosporine at 1 YearImmunosuppressive Efficacy Immunosuppressive Efficacy
Low rates of acute rejection, comparable across armsLow rates of acute rejection, comparable across armsComparable patient and graft survivalComparable patient and graft survival
Safety ProfileSafety ProfileLow rates of serious infections and malignancies, Low rates of serious infections and malignancies, comparable across armscomparable across arms
Addressing Key Areas of Unmet NeedAddressing Key Areas of Unmet NeedProtection of renal function Protection of renal function Lower rates of chronic allograft nephropathyLower rates of chronic allograft nephropathyFavorable trends in CV and metabolic parametersFavorable trends in CV and metabolic parameters
Phase II Study IM103-100, 12 month results, NEJM, 353:770, August 25, 2005Phase II Study IM103Phase II Study IM103--100, 12 month results, NEJM, 353:770, August 25, 2005100, 12 month results, NEJM, 353:770, August 25, 2005
20Not for promotional useNot for promotional use
Cal
cula
ted
GFR
(Glo
mer
ular
Filt
ratio
n R
ate)
C
alcu
late
d G
FR (G
lom
erul
ar F
iltra
tion
Rat
e)
(ml/m
in/1
.73m
(ml/m
in/1
.73m
22 ))
Months After TransplantMonths After Transplant
Belatacept Showed Stable Kidney Belatacept Showed Stable Kidney Function Over Four YearsFunction Over Four Years
1212 1818 2424 3030 3636 4242 4848
Belatacept (N = 102) Belatacept (N = 102) Cyclosporine (N = 26)Cyclosporine (N = 26)
9090
8080
7070
6060
Oral Presentations: 2007 ATC, San Francisco; 2007 ESOT, Prague Oral Presentations: 2007 ATC, San Francisco; 2007 ESOT, Prague
21Not for promotional useNot for promotional use
Belatacept: Initial Registrational Program Belatacept: Initial Registrational Program in Renal Transplantin Renal Transplant
Planning for BLA submission in 1H 09Planning for BLA submission in 1H 09
StudyStudy Study DesignStudy Design EndpointsEndpoints NN
BroadBroad--criteria criteria donordonor
belatacept vs. belatacept vs. cyclosporinecyclosporine
belatacept vs. belatacept vs. cyclosporinecyclosporine
660660
ExtendedExtended--criteria donorcriteria donor
540540
••Death/Graft LossDeath/Graft Loss••Renal function (GFR)Renal function (GFR)••Acute rejectionAcute rejection••Chronic allograft Chronic allograft nephropathynephropathy
22Not for promotional useNot for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development ProgramsFull Development Programs
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in overweight and obese
diabetes patients
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than current standard of care
23Not for promotional useNot for promotional use
Saxagliptin: DPP4 Inhibition Saxagliptin: DPP4 Inhibition –– An Emerging An Emerging Mechanism for Diabetes TreatmentMechanism for Diabetes Treatment
Once a day, oral route of administrationOnce a day, oral route of administrationWeight neutral and low incidence of hypoglycemiaWeight neutral and low incidence of hypoglycemiaIn clinical trials, safety profile comparable to In clinical trials, safety profile comparable to placeboplaceboProlonged glycemic control at low dose due to:Prolonged glycemic control at low dose due to:
–– Highly potent inhibition of DPP4Highly potent inhibition of DPP4–– Sustained binding to DPP4 active siteSustained binding to DPP4 active site
FixedFixed--dose combinations facilitated by:dose combinations facilitated by:–– Unique formulationUnique formulation–– Efficacy at low doseEfficacy at low dose
24Not for promotional useNot for promotional use
Saxagliptin + Metformin Show Improved Saxagliptin + Metformin Show Improved HbAHbA1c1c Reductions at Week 24Reductions at Week 24
* p<0.0001* p<0.0001Bars indicate 95% twoBars indicate 95% two--sided confidence intervalsided confidence intervalPhase III Study Phase III Study --014, ADA, June 2007014, ADA, June 2007
Adjusted Change From BaselineDifference in Adjusted Change from Baseline vs Placebo + Metformin
% C
hang
e in
HbA
% C
hang
e in
HbA
1c1c
PBOPBO+ MET + MET
(N = 175)(N = 175)
SAXA 2.5mgSAXA 2.5mg+ MET+ MET
(N = 186)(N = 186)
SAXA 5mgSAXA 5mg+ MET + MET
(N = 186)(N = 186)
SAXA 10mgSAXA 10mg+ MET+ MET
(N = 180)(N = 180)
*-1
* *-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
--0.730.73 --0.720.72--0.830.83
25Not for promotional useNot for promotional use
Saxagliptin Registrational ProgramSaxagliptin Registrational Program
NDA submission targeted for 1H 08NDA submission targeted for 1H 08Target indicationsTarget indications
–– MonotherapyMonotherapy–– AddAdd--on combination therapy on combination therapy
(metformin, TZD, sulfonylurea)(metformin, TZD, sulfonylurea)–– Initial combination therapy with Initial combination therapy with
metforminmetforminPhase III data presentationsPhase III data presentations
–– ADA, June 2008ADA, June 2008–– EASD, Sept 2008EASD, Sept 2008
26Not for promotional useNot for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development ProgramsFull Development Programs
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in overweight and obese
diabetes patients
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than current standard of care
27Not for promotional useNot for promotional use
PropertiesProperties BenefitsBenefits
Orally active Ease of administration
Rapid onset of action Obviates need for overlap with a parenteral anticoagulant
No food or drug interactions Simplified dosing
Predictable anticoagulant effect
No routine coagulation monitoring
Extra-renal clearance Safe in patients with renal insufficiency
Rapid offset of actionSimplifies management in case of bleed or need for intervention
Optimal benefit/risk profile Treatment benefit outweighs risk
Apixaban target profile
Properties of an Ideal AnticoagulantProperties of an Ideal Anticoagulant
28Not for promotional useNot for promotional use
(mg)(mg)
0
5
10
15
20
25
30
35
40
Daily Dose: 5 10 20 Daily Dose: 5 10 20 5 10 20 5 10 20 QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID Enox WarfEnox Warf Enox WarfEnox Warf
% o
f Pat
ient
s%
of P
atie
nts
Phase II VTE Prevention Study: APROPOS (CV185010), ASH December Phase II VTE Prevention Study: APROPOS (CV185010), ASH December 20062006
Apixaban Demonstrated Greater Efficacy in Preventing Apixaban Demonstrated Greater Efficacy in Preventing VTE / Death Than Standard of Care (Phase II Study)VTE / Death Than Standard of Care (Phase II Study)
ApixabanApixaban ApixabanApixabanBID dosing consistently produced lower rates of VTE/death BID dosing consistently produced lower rates of VTE/death compared with QD dosing with comparable bleeding ratescompared with QD dosing with comparable bleeding rates
VenousVenousThromboembolism (VTE) / Thromboembolism (VTE) /
DeathDeathTotal BleedingTotal Bleeding
29Not for promotional useNot for promotional use
Indication Indication PhasePhase Trial NTrial NVTE prevention (knee replacement)VTE prevention (knee replacement) IIIIII ADVANCEADVANCE--11 3,0003,000
VTE prevention (knee replacement)VTE prevention (knee replacement) IIIIII ADVANCEADVANCE--22 3,0003,000
VTE prevention (hip replacement)VTE prevention (hip replacement) IIIIII ADVANCEADVANCE--3 3 4,0004,000
VTE prevention (medical) VTE prevention (medical) IIIIII ADOPT ADOPT 6,5006,500
Stroke prevention in AF (vs. warfarin)Stroke prevention in AF (vs. warfarin) IIIIII ARISTOTLEARISTOTLE 15,00015,000
Stroke prevention in AF (vs. aspirin)Stroke prevention in AF (vs. aspirin) IIIIII AVERROESAVERROES 5,6005,600
VTE treatment VTE treatment IIIIII In Final PlanningIn Final Planning
Acute Coronary Syndrome Acute Coronary Syndrome IIII APPRAISEAPPRAISE--11 1,8001,800
VTE prevention in cancer VTE prevention in cancer IIII ADVOCATE ADVOCATE 160160
Apixaban Clinical Development:Apixaban Clinical Development:Pursuing Multiple Indications SimultaneouslyPursuing Multiple Indications Simultaneously
VTE VTE –– venous thromboembolismvenous thromboembolism
30Not for promotional useNot for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development ProgramsFull Development Programs
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in overweight and obese
diabetes patients
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than current standard of care
31Not for promotional useNot for promotional use
Execution of BMS Biologics StrategyExecution of BMS Biologics Strategy
AdnexusAdnexus
DomantisDomantis
Therapeutic Therapeutic Area BiologyArea Biology
Ipilimumab(Cancer)
Belatacept(Solid Organ Transplant)
Angiocept(Cancer)
Anti-CD137(Cancer)
Devens Bulk Devens Bulk ManufacturingManufacturing
SyracuseSyracuse
Third Party Third Party ManufacturersManufacturers
ErbituxErbitux(Cancer)(Cancer)
OrenciaOrencia(Rheumatoid (Rheumatoid Arthritis)Arthritis)
32Not for promotional useNot for promotional use
Novel fibronectinNovel fibronectin--based protein therapeutics platform based protein therapeutics platform
Distinct from conventional and domain antibodiesDistinct from conventional and domain antibodies
Freedom to operate in existing MAb spaceFreedom to operate in existing MAb space
E. coliE. coli--based production may result in lower costbased production may result in lower costof goodsof goods
Improved Discovery cycle time and associated lower Improved Discovery cycle time and associated lower cost per development candidatecost per development candidate
Ability to bind two targets simultaneouslyAbility to bind two targets simultaneously
AdnexusAdnexus’’ lead product, Angioceptlead product, Angiocept, in Phase II, in Phase II
Adnexus: The OpportunityAdnexus: The Opportunity
33Not for promotional useNot for promotional use
AngioceptAngiocept
Potent and specific antagonist of VEGFRPotent and specific antagonist of VEGFR--22
Comparable or better activity than AvastinComparable or better activity than Avastinin animal modelsin animal models
Encouraging clinical profileEncouraging clinical profile–– Generally well toleratedGenerally well tolerated–– Favorable and consistent pharmacokinetic Favorable and consistent pharmacokinetic
profileprofile–– Clinical observations of VEGFRClinical observations of VEGFR--2 blockade 2 blockade –– Stable disease demonstrated in several patients Stable disease demonstrated in several patients
with advanced, refractory malignancieswith advanced, refractory malignancies
Transitioned to Phase IITransitioned to Phase II
34Not for promotional useNot for promotional use
2008 Key Data Flow2008 Key Data Flow
OrenciaOrenciaLupus: ACR, Oct 2008Lupus: ACR, Oct 2008Early RA: ACR, Oct 2008Early RA: ACR, Oct 2008RA Prevention: EULAR, June 2008RA Prevention: EULAR, June 2008
SprycelSprycel Solid Tumors: data available 1H 2008Solid Tumors: data available 1H 2008ErbituxErbitux Lung: ASCO, June 2008Lung: ASCO, June 2008
IxempraIxempra MBC MBC --046 survival data: ASCO Breast, Sept 2008046 survival data: ASCO Breast, Sept 2008MBC MBC --048 survival data: SABCS, Dec 2008048 survival data: SABCS, Dec 2008
BelataceptBelatacept Ph III data available: 4Q 2008Ph III data available: 4Q 2008IpilimumabIpilimumab Metastatic melanoma: ASCO, June 2008Metastatic melanoma: ASCO, June 2008
SaxagliptinSaxagliptin Ph III data: ADA, June 2008Ph III data: ADA, June 2008Ph III data: EASD, Sept 2008Ph III data: EASD, Sept 2008
DapagliflozinDapagliflozin Ph IIb data: ADA, June 2008Ph IIb data: ADA, June 2008
PlavixPlavix ACTIVEACTIVE--A data available: 2H 2008A data available: 2H 2008CURRENT data available: 2H 2008CURRENT data available: 2H 2008
ApixabanApixaban Ph II ACS data available: 3Q 2008Ph II ACS data available: 3Q 2008Ph III VTE prevention data: ASH, Dec 2008Ph III VTE prevention data: ASH, Dec 2008